Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Aug 7, 2019; 25(29): 4007-4018
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.4007
Table 1 Demographic data (primary analysis set, n = 229)
nResults
Male gender, n (%)229132 (57.6)
Age (yr)229
Mean (SD)22966.2 (11.5)
≥ 75, n (%)22968 (29.7)
Cancer other than metastatic colorectal cancer, n (%)22820 (8.8)
Duration since diagnosis of primary disease (yr), mean (SD)2262.9 (2.3)
Duration since diagnosis of metastatic disease (yr), mean (SD)2272.0 (1.5)
Metastatic sites, n (%)
Liver229170 (74.2)
Lung22992 (40.2)
Peritoneum22938 (16.6)
Lymph nodes22959 (25.8)
Bone22910 (4.4)
Other22929 (12.7)
BRAF genotyping performed, n (%)22570 (31.1)
If performed, BRAF genotyping
Non-mutated BRAF7062 (88.6)
Mutated BRAF705 (7.1)
BRAF not assessable703 (4.3)
Previous radiotherapy treatment (any cancer), n (%)22762 (27.3)
Previous adjuvant chemotherapya, n (%)227101 (44.5)
Previous chemotherapy for metastatic diseaseb, n (%)229207 (90.4)
Total treatment duration, weeks, mean (SD)
Line 120726.3 (21.9)
Line 216523.0 (20.5)
Line 39719.9 (17.1)
Line 42419.9 (17.6)
Previous radiotherapy for metastatic disease, n (%)30 (13.1)
Abdominal lymph nodes2185 (26.3)
Pelvic22110 (45.5)
Other22118 (81.8)